Table 1 Clinical and pathological data of the series
LODDS1 (LODDS ≤ − 2) | LODDS2 (LODDS > − 2 to ≤ − 1) | LODDS3 (LODDS > − 1) | Total | P-value | |
|---|---|---|---|---|---|
n | 349 | 187 | 12 | 548 | |
Agea | 72 (62–79) | 73 (64–79) | 74 (56–81) | 72 (63–80) | 0.63 |
Grouped Age | 75 (21.5%) | 31 (16.6%) | 3 (25%) | 109 (19.9%) | |
< 60 | 140 (40.1%) | 79 (42.2%) | 3 (25%) | 222 (40.5%) | 0.53 |
> 75 | 134 (38.4%) | 77 (41.2%) | 6 (50%) | 217 (39.6%) | |
Gender | |||||
Female | 151 (43.3%) | 97 (51.9%) | 4 (33.3%) | 252 (46%) | 0.11 |
Male | 198 (56.7%) | 90 (48.1%) | 8 (66.7%) | 296 (54%) | |
Tumoral Location | |||||
Right colon | 128 (36.7%) | 61 (32.6%) | 6 (50%) | 195 (35.6%) | 0.73 |
Transverse colon | 40 (11.5%) | 17 (9.1%) | 1 (8.3%) | 58 (10.6%) | |
Left colon | 30 (8.6%) | 14 (7.5%) | 0 (0%) | 44 (8%) | |
Sigmoid colon | 129 (37%) | 84 (44.9%) | 4 (33.3%) | 217 (39.6%) | |
Unknown | 22 (6.3%) | 11 (5.9%) | 1 (8.3%) | 34 (6.2%) | |
Histology | |||||
Adenocarcinoma | 300 (86.5%) | 151 (81.6%) | 10 (83.3%) | 461 (84.7%) | 0.14 |
Mucinous | 41 (11.8%) | 32 (17.3%) | 1 (8.3%) | 74 (13.6%) | |
Signet-ring cell | 6 (1.7%) | 2 (1.1%) | 1 (8.3%) | 9 (1.7%) | |
Major Size (mm)a | 45 (30–60) | 40 (35–53) | 40 (30–50) | 45 (32–55) | 0.49 |
Grade | |||||
Unknown | 9 (2.6%) | 9 (4.8%) | 1 (8.3%) | 19 (3.5%) | 0.025 |
I | 98 (28.1%) | 52 (27.8%) | 1 (8.3%) | 151 (27.6%) | |
II | 227 (65%) | 108 (57.8%) | 8 (66.7%) | 343 (62.6%) | |
III | 15 (4.3%) | 18 (9.6%) | 2 (16.7%) | 35 (6.4%) | |
Adjuvant Chemotherapy | |||||
No | 262 (75.1%) | 103 (55.1%) | 6 (50%) | 371 (67.7%) | < 0.001 |
Yes | 87 (24.9%) | 84 (44.9%) | 6 (50%) | 177 (32.3%) | |
Number retrieved lymph nodesa | 12 (8–16) | 9 (5–13) | 7 (5.5–11) | 10 (7–15) | < 0.001 |
Cut-off retrieved lymph nodes | |||||
< 12 | 178 (51%) | 120 (64.2%) | 10 (83.3%) | 308 (56.2%) | 0.002 |
≥ 12 | 171 (49%) | 67 (35.8%) | 2 (16.7%) | 240 (43.8%) | |
Number positive lymph nodesa | 0 (0–0) | 2 (1–4) | 6.5 (4.5–10) | 0 (0–1) | < 0.001 |
Lymph Node Ratio | < 0.001 | ||||
0–24 | 349 (100%) | 99 (52.9%) | 0 (0%) | 448 (81.8%) | |
25–60 | 0 (0%) | 80 (42.8%) | 0 (0%) | 80 (14.6%) | |
> 60 | 0 (0%) | 8 (4.3%) | 12 (100%) | 20 (3.6%) | |
Condensed pT6 | |||||
T1–T2 | 84 (24.1%) | 32 (17.1%) | 2 (16.7%) | 118 (21.5%) | 0.16 |
T3–T4 | 265 (75.9%) | 155 (82.9%) | 10 (83.3%) | 430 (78.5%) | |
Condensed pN7 | |||||
N0 | 315 (90.3%) | 31 (16.6%) | 0 (0%) | 346 (63.1%) | < 0.001 |
N1 | 34 (9.7%) | 107 (57.2%) | 2 (16.7%) | 143 (26.1%) | |
N2 | 0 (0%) | 49 (26.2%) | 10 (83.3%) | 59 (10.8%) | |
Condensed TNM stage | |||||
I | 81 (23.3%) | 12 (6.4%) | 0 (0%) | 93 (17%) | < 0.001 |
II | 234 (67%) | 19 (10.2%) | 0 (0%) | 253 (46.2%) | |
III | 34 (9.7%) | 156 (83.4%) | 12 (100%) | 202 (36.8%) | |
Postoperative Death (90 days) | |||||
No | 324 (92.8%) | 167 (89.3%) | 12 (100%) | 503 (91.8%) | 0.27 |
Yes | 25 (7.2%) | 20 (10.7%) | 0 (0%) | 45 (8.2%) | |
Follow-up General Mortality | |||||
No | 234 (67%) | 97 (51.9%) | 3 (25%) | 334 (60.9%) | < 0.001 |
Yes | 115 (33%) | 90 (48.1%) | 9 (75%) | 214 (39.1%) | |
Follow-up Recurrence | 0.004 | ||||
No | 293 (84%) | 139 (74.3%) | 7 (58.3%) | 439 (80.1%) | |
Yes | 56 (16%) | 48 (25.7%) | 5 (41.7%) | 109 (19.9%) | |
Follow-up Time (months)a | 53 (38–66) | 46 (17–63) | 22 (15–49) | 51 (30–64) | 0.002 |